CEL-SCI (NYSE:CVM) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of CEL-SCI (NYSE:CVM) from a sell rating to a hold rating in a research report released on Tuesday morning.

CEL-SCI Stock Performance

Shares of CVM stock opened at $0.56 on Tuesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 0.64 and a quick ratio of 0.18. CEL-SCI has a fifty-two week low of $0.54 and a fifty-two week high of $3.23. The stock’s 50-day moving average is $0.96 and its two-hundred day moving average is $1.15. The firm has a market cap of $35.75 million, a P/E ratio of -0.97 and a beta of 0.69.

CEL-SCI (NYSE:CVM) last issued its earnings results on Thursday, August 15th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Analysts predict that CEL-SCI will post -0.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Tidal Investments LLC acquired a new position in shares of CEL-SCI during the 1st quarter valued at about $27,000. Calton & Associates Inc. bought a new stake in shares of CEL-SCI in the 3rd quarter worth approximately $50,000. Black Diamond Financial LLC lifted its position in shares of CEL-SCI by 35.8% in the 2nd quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after acquiring an additional 19,000 shares during the period. Plotkin Financial Advisors LLC bought a new position in shares of CEL-SCI during the 3rd quarter worth approximately $98,000. Finally, Cutter & CO Brokerage Inc. lifted its position in shares of CEL-SCI by 29.4% during the 2nd quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock worth $126,000 after buying an additional 24,634 shares during the period. 12.08% of the stock is owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.